Anacor Pharmaceuticals, Inc. Announces Positive Preliminary Results From AN2728 MUSE Study In Pediatric And Adolescent Patients With Atopic Dermatitis
Published: Nov 13, 2013
PALO ALTO, Calif.--(BUSINESS WIRE)--Anacor Pharmaceuticals (NASDAQ:ANAC) today announced positive results from its maximal use systemic exposure (MUSE) study of its boron-based phosphodiesterase-4 (PDE-4) inhibitor, AN2728, in pediatric and adolescent patients with atopic dermatitis. The results of this study demonstrate that AN2728 Ointment, 2% appears to be safe, well-tolerated, and efficacious when applied twice daily to patients, ages two to 18 years with atopic dermatitis affecting a very large percentage of their body surface area.
Help employers find you! Check out all the jobs and post your resume.